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In Brief
Ritchie et al. investigate the biology of
GlycA, a known biomarker for short-term
mortality. They reveal GlycA’s long-term
behavior in apparently healthy patients: it
is stable for >10 years and associated
with chronic low-grade inflammation.
Accordingly, GlycA predicts death from
infection up to 14 years in the future.
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The biomarker glycoprotein acetylation (GlycA)
has been shown to predict risk of cardiovascular dis-
ease and all-cause mortality. Here, we characterize
biological processes associated with GlycA by
leveraging population-based omics data and health
records from >10,000 individuals. Our analyses
show that GlycA levels are chronic within individuals
for up to a decade. In apparently healthy individuals,
elevated GlycA corresponded to elevation of myriad
inflammatory cytokines, as well as a gene coexpres-
sion network indicative of increased neutrophil activ-
ity, suggesting that individuals with high GlycA may
be in a state of chronic inflammatory response.
Accordingly, analysis of infection-related hospitali-
zation and death records showed that increased
GlycA increased long-term risk of severe non-local-
ized and respiratory infections, particularly septicae-
mia and pneumonia. In total, our work demonstrates
that GlycA is a biomarker for chronic inflammation,
neutrophil activity, and risk of future severe infec-
tion. It also illustrates the utility of leveraging multi-
layered omics data and health records to elucidateCthe molecular and cellular processes associated
with biomarkers.
INTRODUCTION
The integration of large-scale, systems-wide biomolecular infor-
mation with health records to identify statistical associations
represents a foundation of future studies in ‘‘precision medi-
cine.’’ Early systems-wide studies have elucidated the etiology
of complex diseases in natural human populations (Chen et al.,
2012, 2008; Emilsson et al., 2008; Montoya et al., 2014; Stan-
berry et al., 2013; Wang et al., 2011; Zhang et al., 2013). In doing
so, they have identified biomarkers of potential clinical utility.
Exemplar are recent studies that used nuclear magnetic reso-
nance (NMR) spectroscopy biomarker profiling to identify serum
glycoprotein acetylation (GlycA) levels as a biomarker for risk of
5-year all-cause mortality and incident cardiovascular disease
(CVD) events (Akinkuolie et al., 2014; Fischer et al., 2014).
Fischer et al. showed that elevation of GlycA was predictive of
death from all causes within 5 years in >17,000 generally healthy
individuals from two independent population-based cohorts
(Fischer et al., 2014). Each SD increase of GlycA above the
population mean conferred a 67% and 55% increase in mortality
risk in the 5-year follow-up period for Estonian and Finnish
cohorts, respectively (Fischer et al., 2014). Similarly, Akinkuolieell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc. 293
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Figure 1. Study Guide
(A) Summary of available data for each cohort.
(B) Illustration of overall study flow.et al. investigated GlycA in a recent study of 27,500 initially
healthy women. They found that elevated GlycA was predictive
of 15-year risk of CVD incidence and mortality (Akinkuolie
et al., 2014). In both studies, the predictive capacity of GlycA
was independent of age, sex, modifiable lifestyle risk factors,
medication, and disease prevalence. Other studies on GlycA in
relation to common chronic diseases are rapidly emerging (Akin-
kuolie et al., 2015; Ala-Korpela, 2015); however, the biological
foundation of these associations remains unexplored.
GlycA itself is a complex heterogeneous NMR signal that re-
flects the abundance of mobile N-acetyl sugar groups found
on glycoproteins in circulating blood (Bell et al., 1987; Otvos
et al., 2015). Multiple circulating glycoproteins have been found
to contribute to GlycA, including alpha-1-acid glycoprotein,
alpha-1 antitrypsin, haptoglobin, transferrin (Bell et al., 1987),
and, more recently, alpha-1 antichymotrypsin; however, their
relative contribution to the GlycA signal remains unclear (Otvos
et al., 2015). The glycoproteins contributing to GlycA are
involved in the so-called ‘‘acute-phase response’’ to exogenous
insults, including infection and physical injury. This is a broad set
of systemic biochemical and physiological changes, primarily
driven by cytokine production of inflammatory cells, which occur
immediately following the insult (Gabay andKushner, 1999).With
the exception of transferrin, the circulating concentrations of the
proteins that constitute the GlycA signal are known to increase
during the acute-phase response (Aronsen et al., 1972; Gitlin
and Colten, 1987). Accordingly, the GlycA signal itself is elevated
during the acute phase in patient samples (Bell et al., 1987).
Although GlycA is understood to mark the acute-phase
response, it has also been shown to be elevated in patients
with a diverse range of inflammation-linked chronic conditions,
including rheumatoid arthritis, hypertension, obesity, and meta-
bolic disorders (Bell et al., 1987; Lauridsen et al., 2010; Otvos
et al., 2015; Wu¨rtz et al., 2012, 2014). Clinical assessment of
chronic inflammation is routinely used in patient monitoring,
disease diagnosis, and risk assessment. Currently, the state of
the art for assessing chronic inflammation in the clinic typically
includes quantification of circulating C-reactive protein (CRP),
a single molecular species for which highly sensitive immunoas-294 Cell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc.says are widely available (Pearson et al.,
2003). However, the efficacy of this single
marker may be limited by false-negatives.
Chronic inflammation is likely as heteroge-
neous as the acute-phase response, where
biochemical and physiological changes
are not uniform across inflammatory condi-
tions (Ebersole and Cappelli, 2000; Morley
and Kushner, 1982). Evidence is now
emerging to suggest that elevated CRP
is not a universal feature of chronic inflam-
mation. Importantly, GlycA, a composite
marker of multiple molecular species, has
been shown to predict risk of all-causemortality and CVD, even when adjusting for CRP (Akinkuolie
et al., 2014; Fischer et al., 2014).
This study elucidates the molecular and cellular processes un-
derlying circulating GlycA levels by utilizing a range of omics data
and electronic health records from three large-scale population-
basedcohorts (n=11,825 total).Ourunbiased integrativeanalysis
reveals that GlycA levels are persistent over time and positively
associated with both diverse cytokines in individuals without
recent infection and the neutrophil antimicrobial response. This
suggests that apparently healthy individuals may be in a state
of chronic inflammatory response. Accordingly, we demonstrate
that GlycA is predictive of long-term risk of severe infection using
a largeprospective cohort with nearly 14 years of follow-uphealth
records. The overall study flow is illustrated in Figure 1.
RESULTS
Study Data
In this study, we analyzed data collected by three population-
based studies (Supplemental Experimental Procedures). The
Dietary, Lifestyle, and Genetic Determinants of Obesity and
Metabolic syndrome (DILGOM) Study is a cross-sectional cohort
of 579 individuals (300 female; 52%)25–74years old (Inouyeet al.,
2010a, 2010b). The 1997 collection of the FINRISK Study is a
cross-sectional cohort of 7,599 individuals (3,822 female; 50%)
24–74 years old with disease events followed prospectively via
nation-wide electronic health records (Borodulin et al., 2015;
Wu¨rtz et al., 2015). TheCardiovascular Risk in Young Finns Study
(YFS) is a longitudinal population-basedstudyof 3,596 individuals
(1,832 female; 51%) recruited during childhood in 1980 (Raitakari
et al., 2008). In this study, data were available from the 2001,
2007, and 2011 follow-up collections (YFS2001, YFS2007, and
YFS2011, respectively) (Wu¨rtz et al., 2014). By the 2011 follow-
up, individuals were 34–49 years old. Clinical and demographic
characteristics for each study are summarized in Table 1.
For all studies, NMR biomarker profiling data, including data
for GlycA, were available (Soininen et al., 2009), as were CRP
immunoassays. To fine-map the GlycA signal, alpha-1-acid
glycoprotein, alpha-1 antitrypsin, haptoglobin, and transferrin
Table 1. Cohort Characteristics
Characteristic YFS 2001 YFS 2007 YFS 2011 DILGOM FINRISK
Collection year 2001 2007 2011 2007 1997
Number of individuals 2,232 2,159 2,041 579 7,599
Number (and %) of women 1,234 (55%) 1,185 (55%) 1,112 (54%) 300 (52%) 3,822 (50%)
Mean age in years (and
range)
31.7 (24–39) 37.7 (30–45) 41.9 (34–49) 52.1 (25–74) 48.3 (24–74)
Body mass index (kg/m2) 25.1 ± 4.4 26.0 ± 4.8 26.5 ± 5.1 26.8 ± 4.7 26.7 ± 4.5
GlycA (mmol/l) 1.4 ± 0.2 1.6 ± 0.3 1.6 ± 0.2 1.6 ± 0.2 1.4 ± 0.2
Triglycerides (mmol/l) 1.3 ± 0.8 1.4 ± 0.9 1.3 ± 0.8 1.3 ± 0.6 1.5 ± 1.1
CRP (mg/l) 1.9 ± 3.8 1.9 ± 3.8 1.7 ± 3.2 2.7 ± 5.7 2.5 ± 5.3
Number (and %):
Recent febrile infection 112 (5.0%) 95 (4.4%) 93 (4.6%) – –
Use of antihypertensive
therapy
58 (2.6%) 146 (6.8%) 197 (9.7%) 118 (20%) 1,015 (13%)
Use of lipid-lowering therapy 7 (0.3%) 45 (2.1%) 74 (3.6%) 86 (15%) 269 (0.4%)
Prevalent diabetes – – 35 (1.3%) 61 (10%) 440 (5.8%)
Incident diabetes – – – 8 (1.4%) 605 (8.0%)
Prevalent CVD – – 20 (0.7%) 17 (2.9%) 263 (3.5%)
Incident CVD – – – 7 (1.2%) 802 (11%)
Prevalent cancer – – 40 (1.4%) 18 (3.1%) 180 (2.4%)
Incident cancer – – – 11 (1.9%) 12 (0.2%)
Prevalent immunodeficiency – – 10 (0.4%) 0 (0%) 8 (0.1%)
Incident immunodeficiency – – – 0 (0%) 12 (0.2%)
Total number of deaths – – – 15 (2.6%) 839 (11%)
Number of glycoprotein
assays
– – – 579 –
Alpha-1-acid glycoprotein
(g/l)
– – – 0.8 ± 0.2 –
Alpha-1 antitrypsin (g/l) – – – 1.2 ± 0.2 –
Haptoglobin (g/l) – – – 1.1 ± 0.5 –
Transferrin (g/l) – – – 2.7 ± 0.4 –
Number of cytokine assays – 2,159 – – –
Cell count data – – 2,021 – –
Gene expression profiling:
number
– – 1,649 518 –
Data are reported as the mean ± SD unless otherwise indicated. Prevalent disease indicates events occurring prior to sample collection, while incident
disease indicates events occurring after sample collection. For the YFS, a disease was considered prevalent if it occurred any time prior to the 2011
sample collection for any of the 2,766 individuals participating at any one time point. Cytokine characteristics are reported in Table S1. Dashes indicate
that data are not applicable.were quantified by immunoturbidimetric methods in the
DILGOM Study. Multiplexed cytokine panels were performed
for YFS2007. Cytokine characteristics are reported in Table S1.
Fasting whole-blood transcriptomic data (Illumina HT-12 arrays)
were available for the DILGOM Study and YFS2011. Electronic
health records were collated for the FINRISK Study only. There
was an insufficient number of endpoint events for GlycA survival
analysis in the DILGOMStudy due to small sample size and short
follow-up time. Because of their relative youth and short follow-
up time, there were also insufficient numbers of endpoint events
in the YFS. Unless otherwise noted, all molecular measurements
in all cohorts were performed on fasting serum samples.
Protocols and processing details for each platform and study
are described in the Supplemental Experimental Procedures.CSpecific Glycoprotein Levels Contributing to GlycA in a
Population-Based Study
In contrast to previous studies that used protein standards to de-
convolute the GlycA signal (Bell et al., 1987; Otvos et al., 2015),
we utilized a population-based approach through the DILGOM
Study to determine the relative contributions of serum alpha-1-
acid glycoprotein, alpha-1 antitrypsin, haptoglobin, and trans-
ferrin levels to GlycA (Supplemental Experimental Procedures).
As expected, we found that all four glycoproteins significantly
contributed to GlycA signal intensity. Univariable linear regres-
sion indicated that each SD increase of alpha-1-acid glycopro-
tein, haptoglobin, alpha-1 antitrypsin, and transferrin corre-
sponded to a 0.54 (p = 2 3 1053), 0.52 (p = 9 3 1040), 0.29
(p = 3 3 1012), and 0.20 (p = 1 3 106) SD increase of GlycA,ell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc. 295
Figure 2. GlycA Summarizes Low-Grade Inflammation Cytokine
Activity
Median difference in concentration (SDs) relative to the population mean for 36
assayed cytokines and CRP for ten GlycA-risk categories in the 2007 collec-
tion of the YFS cohort. The right axis denotes the change in SD units of GlycA
per SD increase of each cytokine or CRP, adjusting for age and sex in the YFS
cohort. *p < 0.001 (Bonferroni corrected for the number of cytokines). Table S1
gives the full name and Uniprot identifier for each cytokine.
See also Table S1.respectively. Of the individuals in the top 10% for the GlycA
levels, 40%were also in the top decile for alpha-1-acid glycopro-
tein levels, as were 43% for haptoglobin, 29% for alpha-1 anti-
trypsin, and 15% for transferrin. Pairwise correlations among
the glycoproteins were either positive or, in the case of alpha-
1-acid glycoprotein and transferrin, not significant. These
analyses indicate that the GlycA signal is not dominated by
any single glycoprotein; thus, GlycA is treated as a composite
signal in all subsequent analyses.
GlycA Levels in Acute Phase, Chronicity over Time, and
Relationship with Myriad Cytokines
All YFS collections contained samples from individuals reporting
febrile infection within 2 weeks prior to sample collection. In
these individuals, we observed modest elevation of GlycA in
individuals from all YFS collections (mean increase of 0.41 SD;296 Cell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc.Figure S1), consistent with GlycA’s role as a positive acute-
phase reactant. Among YFS individuals not reporting a recent
febrile infection, there was a strong autocorrelation of GlycA
levels within individuals across all three time points (mean Pear-
son r = 0.43). Of the top 10%of individuals byGlycA level in 2001,
20%were also in the top decile in 2007, and 19%were also in the
top decile in 2011. Individuals reporting a recent febrile infection
were no more likely than others to have elevated GlycA levels at
any subsequent time point.
Given that elevated GlycA levels correlated with both the
acute-phase response and were stable over time, we asked
whether GlycA was associated with inflammatory signatures in
apparently healthy individuals. We utilized multiplex cytokine
panels assayed in YFS2007 serum samples (Supplemental
Experimental Procedures) from individuals reporting no recent
febrile infections and observed a large number of robust associ-
ations (Bonferroni-adjusted p < 0.001): 30 of 36 tested cytokines
were significantly associated with GlycA (Figure 2). The concen-
trations of 29 cytokines, with both anti- and pro- inflammatory
roles, increased along with the GlycA signal (Figure 2). Only
cutaneous T-cell-attracting chemokine (CTACK) showed a
significant negative association with GlycA (Figure 2). Cytokine
concentration changes associated with GlycA were relatively
modest, with even the top decile of GlycA levels corresponding
to cytokine elevations of 0.11–0.48 SD on average (Figure 2).
Together, these results suggest an association between
elevated GlycA and systemic low-grade inflammation in an
apparently healthy population. It was not possible to test
whether cytokine concentrations were stable over time, like
those of GlycA, because cytokine panels were not available for
YFS2001 or YFS2011.
A Transcriptional Subnetwork Associated with GlycA
When put in the context of previous studies, our results suggest
that, in addition to marking the acute-phase response (Bell et al.,
1987), high GlycA levels may also mark chronic inflammation
in apparently healthy individuals. This suggests an intimate
connection between the circulating, systemic concentration of
GlycA and cellular-level changes in physiology. To gain insight
into cellular processes associated with elevated GlycA, we uti-
lized whole-blood transcriptome profiling in the DILGOM and
YFS2011 cohorts. We inferred weighted gene coexpression
network modules (Zhang and Horvath, 2005) in the DILGOM
cohort and then tested each module for an association with
the GlycA signal (Supplemental Experimental Procedures).
Briefly, the full gene coexpression network was inferred as the
pairwise Spearman correlation between all microarray probes.
This was converted to a measure of network adjacency through
a soft-threshold power transform. Modules were then detected
through a dynamic tree cut algorithm on the topological overlap
similarity of probe adjacencies. A summary expression vector
(first principal component) was calculated for each module
and used to test for the association with GlycA. Models were
adjusted for age, sex, and, additionally, serum triglyceride levels,
which have been shown tomodify themultivariable effect of lipo-
protein concentrations on the GlycA signal and associated mor-
tality risk (Fischer et al., 2014). Significantly associated modules
were subsequently tested for replication in the YFS cohort using
NetRep (v0.10.4), a rapid permutation-based approach of
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Figure 3. Neutrophil Gene Coexpression Module Associated with GlycA
(A and B) Probe coexpression (Spearman correlation) in the DILGOM cohort (A) and replication in the YFS2011 cohort (B). See Table S3 for module gene details.
Symbols above gene symbol indicate expression in neutrophils (#), whether its product is located in neutrophil granules (%), and whether its product has
antimicrobial functionality (*). See Table S5 for a summary of the literature for each gene.
(C) Replication of GlycA association in both cohorts. Associations were assessed using a linear regression of GlycA on themodule summary expression adjusting
for age, sex, and triglycerides. Magnitude corresponds to change in SD units of GlycA per SD increase of neutrophil module expression. CI, confidence interval.
(D) The top enriched GO biological process terms. A full list of significant GO terms and KEGG pathway enrichments can be found in Table S4.
(E) Association of neutrophil module expression with alpha-1-acid glycoprotein, haptoglobin, alpha-1 antitrypsin, and transferrin in the DILGOM cohort in a
multivariable linear regression. Magnitude corresponds to change in SD units of GlycA per SD increase of each respective acute-phase glycoprotein.
(F) Boxplots showing association with recent febrile infection (self-reported) (n = 72 with febrile infection, and n = 1,550 without). T-test difference, 95% confi-
dence interval, and p value are reported. GlycA and triglyceride levels were log-transformed. All continuous measurements were standardized.
See also Tables S3, S4, and S5.network topology features (Supplemental Experimental Proce-
dures) (Langfelder et al., 2011). NetRep is available at https://
github.com/InouyeLab/NetRep/.
We identified 40 coexpression modules within the DILGOM
whole-blood expression data, of which 3were significantly asso-
ciated with GlycA after adjusting for multiple testing (p < 0.001).
One module’s network topology and GlycA association was
replicated in the YFS2011 whole-blood expression data (permu-
tation test p value < 0.01 for all network-based statistics and
GlycA association p value < 0.001; Table S2). We subsequently
performed in-depth analysis of the module (Figure 3) and its 27
genes (Table S3). For this module, single-gene associations
with GlycA were consistent with the whole-module association
with GlycA.
The enriched GO processes and KEGG pathways of the
module largely implicated innate immune response to microbes
(Table S4). Consistent with this, module expression was elevated
by 0.61 SDs (p = 3 3 104) in individuals reporting recent febrile
infection (Figure 3). Most genes in the preserved module were
primarily reported in the literature as coding for antimicrobial
peptides synthesized in and secreted from neutrophil granules
(14 genes, 52%; Figure 3; Table S5). Genes with antimicrobial
function constituted 11 of the top 14 genes when ranked by
mean intramodular connectivity across datasets (Table S3), a
topological measure known to correspond to relative biological
importance (Langfelder et al., 2013). A further three genes
coded for proteins serving a non-antimicrobial role in neutro-Cphil-granule-associated processes (Table S5), and two genes
coded for proteins expressed on the surface of neutrophils
(Table S5). Since a majority of these genes have well-character-
ized antimicrobial roles in neutrophil granules (Faurschou and
Borregaard, 2003), we refer hereinafter to this module as the
neutrophil module.
Neutrophils are the dominant white blood cell type in adult
humans, but their abundance varies in populations and within
individuals over time (Summers et al., 2010). While neutrophil
cell counts were not available, we observed a strong positive as-
sociation between overall leukocyte abundance and elevated
neutrophil module summary expression (b = 0.24 SD leukocyte
abundance increase per SD increase of neutrophil module
expression, p = 2 3 1017) in the YFS2011, suggesting that
elevated neutrophil module expression may be associated, to
some extent, with increased circulating neutrophil abundance.
Adjustment of the GlycA model for leukocyte abundance
showed that neutrophil module expression retained a strong as-
sociation with GlycA; however, both the module and leukocyte
abundance were highly significant (b = 0.09, p = 2 3 106, and
b = 0.15, p = 2 3 1015, respectively), indicating that increased
GlycA corresponds to increased production of both antimicro-
bial peptides and circulating leukocytes. Neutrophil module
expression was significantly associated with alpha-1-acid glyco-
protein and haptoglobin (p = 13 104 and p = 0.01, respectively;
Figure 3E). Both proteins are synthesized in and secreted from
neutrophil granules (Theilgaard-Mo¨nch et al., 2005, 2006),ell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc. 297
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Figure 4. GlycA Predicts Hospitalization
and Death from Infectious Diseases
(A and B) Hazard ratios (HRs) for fatal events from
broad infection-related categories for (A) in-
dividuals with GlycA concentrations above the
population median, and (B) risk of fatal events (red)
or hospitalization (white) conferred per SD incre-
ment of log-transformed GlycA for infection-
related diagnoses with more than ten events in the
FINRISK 1997 cohort. 7,599 apparently healthy
individuals from the general population were pro-
spectively observed over a 13.8-year follow-up
period. Cox models were adjusted for age, sex,
triglycerides, and incidence of the same diagnosis
in the 10 year prior to sample collection. Numbers
in square brackets indicate the International
Classification of Diseases (tenth edition; ICD-10)
code blocks for the corresponding diagnosis.
Figure S2 gives an extended breakdown into in-
dividual ICD-10 diagnosis codes, and Figure S3
shows sensitivity analyses of HRs when adjusted
for prevalent chronic diseases, compared to CRP,
and adjusted for CRP. CI, confidence interval.
See also Figures S2 and S3.suggesting an overabundance of neutrophils and that their
granule content may directly contribute to elevated GlycA.
GlycA Is Associated with Risk of Hospitalization and
Death from Microbial Infection
Because GlycA and the microbial-associated inflammatory
response were statistically associated, and it is known that the
inflammatory response correlates with adverse outcomes in
the clinic, we hypothesized that GlycA level may also be reflec-
tive of future infection severity risk. We asked whether there
was a relationship between risk of future hospitalization or death
and elevated GlycA levels. To do this, we assessed infection-
related causes of hospitalization or death in a population-based
collection of 7,599 individuals from FINRISK 1997who had base-
line GlycA profiles and electronic health records with 13.8 years
of follow-up (Supplemental Experimental Procedures). Cox pro-
portional hazards models were fitted to each infectious disease
cause, with adjustments for age, sex, triglycerides, and hospital-
ization due to the same diagnosis category in up to 10 years prior
to the GlycA measurement.
We observed strong associations between baseline GlycA
levels in FINRISK 1997 and increased risk of hospitalization
and death from non-localized infections (hospitalization HR =
1.40 per SD of GlycA, p = 2 3 109, cases = 585; death HR =
2.36, p = 8 3 105, cases = 29) and respiratory infections (hos-
pitalization hazard ratio [HR] = 1.48, p = 3 3 1012, cases =
571; death HR = 1.39, p = 9 3 103, cases = 113) during the
13.8 years of follow-up (Figure 4). Individuals with GlycA levels
above the population median were at more than 5-fold
increased risk of death from non-localized infections in subse-
quent years (p = 7 3 103, cases = 29; Figure 4). The increased298 Cell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc.risk of death from non-localized infections
was largely attributable to septicemia
(HR = 2.25, p = 4 3 103, cases = 18),
while death from respiratory infectionwas largely attributable to pneumonia (HR = 1.38, p = 1 3
102, cases = 113) (Figure 4B). GlycAwas also broadly predictive
of hospitalization from infection, including fungal infections and
localized infections of the skin, bones, joints, intestinal, and uri-
nary system (Figure 4B). Adjustment of GlycA models for preva-
lent CVD, diabetes, cancer, immunodeficiencies, and obesity
made little difference to GlycA HRs for future risk of hospitaliza-
tion and death from infection (Figure S3A). GlycA displayed
stronger prediction on average than CRP across all infection-
related events (Figure S3B), and adjustment of the models for
CRP only slightly attenuated the GlycA HRs (Figure S3C). Taken
together, these results suggest that apparently healthy individ-
uals with elevated baseline levels of GlycA are at increased risk
for severe infection events for up to 14 years in the future.
DISCUSSION
GlycA is a composite NMR-based signal related to changes
in multiple circulating glycoproteins (Bell et al., 1987; Otvos
et al., 2015), which are, themselves, responsive to myriad in-
flammatory stimuli (Gabay and Kushner, 1999). Previous studies
have shown that GlycA is predictive of long-term risk for CVD
events and all-cause mortality (Akinkuolie et al., 2014; Fischer
et al., 2014). In this study, we characterized the molecular and
cellular processes underlying GlycA variation in circulation. In
apparently healthy individuals, we have shown that GlycA
can be chronically elevated for periods of up to a decade; in
individuals with high GlycA, widespread, modest elevation of
numerous cytokines are suggestive of a prolonged low-grade
inflammatory state. Accordingly, we identified a robust tran-
scriptional module in whole blood that was strongly positively
associated with GlycA levels and enriched for innate immune
response genes—specifically, those with neutrophil antimicro-
bial function. Elevated GlycA levels had long-term ramifications
for risk of infection: high GlycA levels correlated with an
increased risk of hospitalization and death from diverse infec-
tions—particularly septicemia and pneumonia—that persists
for over a decade.
The question remains as to the cause of GlycA-associated
chronic inflammation. Taken together, our results suggest
multiple potential scenarios where apparently healthy individuals
with high GlycA levels have (1) persistent but clinically silent,
low-grade microbial infection(s), (2) a past severe infection
event that results in modest chronic inflammation, (3) low-grade,
chronic inflammation that mimics an anti-microbial response, or
(4) a combination of these. This GlycA-related immune response
was characterized by a gene coexpression network that
harbored a clear neutrophil transcriptional signature indicative
of antimicrobial function (Faurschou and Borregaard, 2003).
Once recruited to the site of infection, neutrophils secrete antimi-
crobial peptides from their granules into the extracellular matrix
and into phagosomes that surround microbes. They also
form neutrophil extracellular traps (NETs): extracellular fibers
composed of neutrophil DNA and granule antimicrobial peptides
(Brinkmann et al., 2004; Urban et al., 2009). Neutrophil antimicro-
bial peptides are generally cytotoxic, damaging and degrading
proximal tissue. Aberrantly increased neutrophil activity has
been observed in a range of chronic inflammatory conditions
that are generally thought to be independent of microbial infec-
tion, including rheumatoid arthritis (Branzk and Papayannopou-
los, 2013; Wright et al., 2010), and increased neutrophil
abundance itself has been shown to have predictive capacity
for long-term mortality and myocardial infarction event risk
(Horne et al., 2005).
Consistent with the diverse ramifications of neutrophil-driven
inflammation, Warnatsch et al. recently reported a causal link
between cholesterol, NET formation, and pro-inflammatory
response driving atherosclerotic plaque growth (Warnatsch
et al., 2015). Notably, two of the genes we identify as part of
the neutrophil module, ELANE and MPO, have key roles in
NET formation (Papayannopoulos et al., 2010). Furthermore,
the long-term risk of severe infection events in apparently
healthy individuals with elevated GlycA levels was consistent
with overactivity of immune response, though GlycA may
not necessarily play a causal role. Overactivity of immune
response from severe infection events, such as sepsis and
influenza, is known to cause tissue damage and organ
dysfunction through hypercytokinemia (Tisoncik et al., 2012),
and baseline elevation of circulating cytokines correlated with
GlycA may contribute to its association with hospitalization
and mortality risk. While our findings are largely observational,
the prospect of systematic integration of prior medical inter-
ventions may yield causal relationships. In addition, an imme-
diately fruitful avenue of research may be in vivo assays of
neutrophil function, using neutrophils derived from individuals
with variable GlycA levels.
This study demonstrates the utility of an approach that inte-
grates diverse omics data and long-term follow-up of health re-
cords to uncover putative cellular-level processes associated
with a recently uncovered biomarker. As multi-omics studiesCbecome increasingly common, biomarker associations with
medical histories and health outcomes are likely to improve
both patient care and our knowledge of the basic biological
mechanisms underlying human disease. This study represents
a potentially useful strategy for leveraging omics information
for future studies in precision medicine.
EXPERIMENTAL PROCEDURES
Full experimental procedures can be found in the Supplemental Experimental
Procedures. For YFS, ethics were approved by the Joint Commission on
Ethics of the Turku University and the Turku University Central Hospital; for
DILGOM, ethics were approved by the Coordinating Ethical Committee of
the Helsinki and Uusimaa Hospital District; and for FINRISK, ethics were
approved by the ethical committee of the National Public Health Institute,
Finland (Supplemental Experimental Procedures).
Data Collection and Quantification
Concentrations of GlycA and triglycerides were quantified from serum sam-
ples using a proton NMR platform (Soininen et al., 2009). Concentrations of
high-sensitivity CRP and the four glycoproteins were quantified from serum
using immunoturbidimetric assays, and the 36 cytokines were quantified using
multiplex cytokine panels. Genome-wide gene expression profiling was
carried out on whole blood using the Illumina HT12 platform, and blood cell
count analysis was carried out using flow cytometry. Incident event data
were obtained from the Finnish National Hospital Discharge Register and the
National Causes of Death Register (Lim et al., 2014). Clinical characteristics
were also obtained from survey questions. Data type availability, sample sizes,
and cohort characteristics are provided in Table 1.
Network Analysis
Network inference and module detection were performed in the DILGOM
cohort using weighted gene coexpression network analysis (WGCNA) (Zhang
and Horvath, 2005). Network inference was adjusted for age and sex. The
soft-threshold power used for network construction was 5 (Figure S4A). Repli-
cation of the three GlycA-associated modules was assessed in the YFS2011
cohort through permutation testing of seven network-based statistics (Lang-
felder et al., 2011) (Table S6), using a pre-release of the NetRep R package
(version 0.10.4, available at https://github.com/InouyeLab/NetRep/releases/
tag/v0.10.4). For this purpose, the network inference component of WGCNA
was performed on the YFS2011 gene expression. The soft threshold power
was 4 (Figure S4b). Summary expression profiles were calculated as the eigen-
vector of the first principal component of each module’s gene expression
matrix. We use the shorthand ‘‘neutrophil module expression’’ to refer to the
neutrophilmodule’s summary expression profile throughout the text.Over-rep-
resentation analysis of Gene Ontology (GO) terms and KEGG pathways was
performed using the web tool, GeneCoDis (Carmona-Saez et al., 2007).
Statistical Analyses
A natural log-transform was applied to GlycA, each glycoprotein, triglycerides,
and leukocyte abundance. A rank-based inverse normal transform was
applied to each cytokine. Each measurement, including each module’s sum-
mary expression, was standardized to SD units. All regression models were
adjusted for age and sex, and models testing association between GlycA
and module expression were additionally adjusted for triglycerides. HRs of
GlycA for hospitalization or death were assessed by Cox proportional-hazard
models using age as the timescale and adjusted for sex, triglycerides, and
prior occurrence of the diagnosis category within ten years prior to sample
collection. Sensitivity analyses were performed by (1) additionally adjusting
for prevalent chronic diseases or inflammatory disorders, (2) replacing GlycA
for CRP and, (3) adjusting GlycA for CRP.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cels.2015.09.007.ell Systems 1, 293–301, October 28, 2015 ª2015 Elsevier Inc. 299
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